Smartleaf Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Smartleaf Asset Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$722	Hold	12	–	–	﹤0.01%	3148
2026 Q1	$667	Sell	12 -4	-25%	-$184	﹤0.01%	3179
2025 Q4	$706	Buy	+16	New	+$672	﹤0.01%	3221

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Smartleaf Asset Management's XENE Position: Q2 2026 in Review

Smartleaf Asset Management held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 12 shares worth $722. The position accounts for ﹤0.01% of the portfolio, ranked #3148.

Smartleaf Asset Management first reported a position in XENE in Q4 2025 and has held it in 3 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Smartleaf Asset Management held 12 shares of Xenon Pharmaceuticals worth $722 as of Q2 2026.
Smartleaf Asset Management left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #3148 holding.
Smartleaf Asset Management first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.